PROGNOSTIC INFLUENCE OF BETA-2-MICROGLOBULIN IN MULTIPLE-MYELOMA

被引:0
|
作者
ORTEGA, F
GONZALEZ, M
MORO, MJ
GASCON, A
DUARTE, I
MARTIN, M
HERNANDEZ, J
JIMENEZGALINDO, R
PORTERO, JA
SANZ, M
CASANOVA, F
GUERRAS, L
ROMERO, M
SANMIGUEL, JF
机构
[1] UNIV SALAMANCA,HOSP CLIN,SERV MED NUCL,SALAMANCA,SPAIN
[2] GRP COOPERAT CASTELLANO LEONES,CASTELLANO LEONES,SPAIN
来源
MEDICINA CLINICA | 1992年 / 99卷 / 17期
关键词
D O I
暂无
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
BACKGROUND: The aim of the present study was to compare the prognostic influence of beta2-microglobulin (B2M) corrected according to renal function versus the uncorrected form and relate these values with other characteristics of the disease in a series of patients with multiple myeloma (MM). METHODS: The serum levels of B2M were determined by the radioimmunoassay method (RIA) in 107 patients with newly diagnosed MM and the prognostic influence of B2M was statistically evaluated with univariant and multivariant analysis. RESULTS: The mean value of B2M obtained in patients with MM was 7.8 +/- 8.0 mug/ml, with a median of 5 mug/ml. Ninety percent of the patients studied presented serum values of B2M higher than the normal limit. The value of B2M corresponding to the median of the series (5 mug/ml) separated two groups of patients with different survival (48 vs 19 months) (p = 0.0001). Similarly, the most discriminative value of corrected B2M in agreement with creatinine (2.5 mug/ml) permited the differentiation of two groups of patients although the differences in survival were less significant (36 vs 26 months, p = 0.03) demonstrating its lesser influence as a prognostic factor with respect to the uncorrected B2M. In contrast, a significant association was observed between high values of B2M and Bence Jones myeloma, clinical stage III, anemia, renal failure and intense involvement of the general state. Multivariant analysis demonstrated that B2M plays a greater prognostic role when used as a discrete rather than a continuos variable and that together with the degree of involvement of the general state, serum albumin and the proportion of plasma cells in the bone marrow, they make up the best set of variables for the prediction of prognosis in patients with MM. CONCLUSIONS: Beta2-Microglobulin is one of the most important independent prognostic factors in multiple myeloma with its prognostic value being greatest when used uncorrected according to the values of creatinine.
引用
收藏
页码:645 / 648
页数:4
相关论文
共 50 条
  • [1] THE BETA-2-MICROGLOBULIN INDEX IN THE PROGNOSTIC EVALUATION OF MULTIPLE-MYELOMA
    PASQUALETTI, P
    CASALE, R
    COLANTONIO, D
    [J]. BRITISH JOURNAL OF HAEMATOLOGY, 1991, 77 (03) : 437 - 438
  • [2] THE PROGNOSTIC-SIGNIFICANCE OF SERUM BETA-2-MICROGLOBULIN IN MULTIPLE-MYELOMA
    NORFOLK, D
    CHILD, JA
    KERRUISH, S
    COOPER, EH
    WARD, AM
    [J]. BRITISH JOURNAL OF CANCER, 1980, 42 (01) : 190 - 190
  • [3] PRETREATMENT SERUM BETA-2-MICROGLOBULIN IN MULTIPLE-MYELOMA
    BRENNING, G
    SIMONSSON, B
    KALLANDER, C
    AHRE, A
    [J]. BRITISH JOURNAL OF HAEMATOLOGY, 1986, 62 (01) : 85 - 93
  • [4] PROGNOSTIC FACTORS IN MULTIPLE-MYELOMA - ROLE OF BETA-2-MICROGLOBULIN AND THYMIDINE KINASE
    DIEM, H
    FATEHMOGHADAM, A
    LAMERZ, R
    [J]. CLINICAL INVESTIGATOR, 1993, 71 (11): : 918 - 923
  • [5] PROGNOSTIC-SIGNIFICANCE OF PRETREATMENT SERUM BETA-2-MICROGLOBULIN LEVELS IN MULTIPLE-MYELOMA
    SCARFFE, JH
    ANDERSON, H
    PALMER, MK
    CROWTHER, D
    [J]. EUROPEAN JOURNAL OF CANCER & CLINICAL ONCOLOGY, 1983, 19 (10): : 1361 - 1364
  • [6] SERUM FERRITIN AND BETA-2-MICROGLOBULIN IN PATIENTS WITH MULTIPLE-MYELOMA
    LINKESCH, W
    LUDWIG, H
    [J]. CANCER DETECTION AND PREVENTION, 1983, 6 (1-2): : 297 - 301
  • [7] PROGNOSTIC FACTORS IN MULTIPLE-MYELOMA WITH SPECIAL ATTENTION TO BETA-2-MICROGLOBULIN AND THYMIDINE-KINASE
    FATEHMOGHADAM, A
    DIEM, H
    MUNDEL, M
    LAMERZ, R
    WILMANNS, W
    [J]. JOURNAL OF CLINICAL CHEMISTRY AND CLINICAL BIOCHEMISTRY, 1988, 26 (11): : 741 - 741
  • [8] SERUM BETA-2-MICROGLOBULIN - A REAL IMPROVEMENT IN THE MANAGEMENT OF MULTIPLE-MYELOMA
    VANDOBBENBURGH, OA
    RODENHUIS, S
    OCKHUIZEN, T
    WELTEVREDEN, E
    HOUWEN, B
    FIDLER, V
    MEIJER, S
    MARRINK, J
    [J]. BRITISH JOURNAL OF HAEMATOLOGY, 1985, 61 (04) : 611 - 620
  • [9] SERUM BETA-2-MICROGLOBULIN AT REMISSION AND RELAPSE IN PATIENTS WITH MULTIPLE-MYELOMA
    BRENNING, G
    WIBELL, L
    BERGSTROM, R
    [J]. EUROPEAN JOURNAL OF CLINICAL INVESTIGATION, 1985, 15 (05) : 242 - 247
  • [10] DIURNAL-VARIATIONS OF SERUM BETA-2-MICROGLOBULIN IN MULTIPLE-MYELOMA
    PASQUALETTI, P
    CASALE, R
    COLANTONIO, D
    COLLACCIANI, A
    NATALI, G
    [J]. LIFE SCIENCES, 1991, 49 (06) : 435 - 438